Pathogenesis of ankylosing spondylitis

Nature Reviews Rheumatology

Volumn 6, Issue 7, 2010, Pages 399-405

  Tam, Lai Shan ^a   Gu, Jieruo ^b   Yu, David ^c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN K; DICKKOPF 1 PROTEIN; HLA B27 ANTIGEN; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 6 RECEPTOR; INTERSTITIAL COLLAGENASE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; OSTEOCLAST DIFFERENTIATION FACTOR; STROMELYSIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; WNT PROTEIN;

ANKYLOSING SPONDYLITIS; AUTOIMMUNITY; BONE DESTRUCTION; BONE EROSION; DRUG RESPONSE; ENTHESITIS; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITY; HUMAN; INFLAMMATION; NONHUMAN; OSSIFICATION; OSTEOPHYTE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SPINAL PAIN; BONE REMODELING; GENETICS; SPONDYLITIS, ANKYLOSING;

BONE REMODELING; HLA-B27 ANTIGEN; HUMANS; SPONDYLITIS, ANKYLOSING;

EID: 77954311602     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.79     Document Type: Review

References (97)

1. Braun, J. & Sieper, J. Ankylosing spondylitis. Lancet 369, 1379-1390 (2007).
2. Sieper, J., Rudwaleit, M., Khan, M. A. & Braun, J. Concepts and epidemiology of spondyloarthritis. Best Pract. Res. Clin. Rheumatol. 20, 401-417 (2006).
3. Goh, L. & Samanta, A. A systematic MeDLiNe analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol. Int. 29, 1123-1135 (2009).
4. McLeod, C., et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol. Assess. 11, 1-158, iii-iv (2007).
5. Zochling, J., et al. ASAS/eULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 65, 442-452 (2006).
6. Schett, G., Landewé, R. & van der Heijde, D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann. Rheum. Dis. 66, 709-711 (2007).
7. van der Heijde, D., et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58, 3063-3070 (2008).
8. van der Heijde, D., et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324-1331 (2008).
9. van der Heijde, D., et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 11, R127 (2009).
10. Brewerton, D. A., et al. Ankylosing spondylitis and HL-A 27. Lancet 1, 904-907 (1973).
11. Schlosstein, L., Terasaki, P. i., Bluestone, R. & Pearson, C. M. High association of an HL-A antigen, W27, with ankylosing spondylitis. N. Engl. J. Med. 288, 704-706 (1973)
12. Cawley, M. i., Chalmers, T. M., Kellgren, J. H. & Ball, J. Destructive lesions of vertebral bodies in ankylosing spondylitis. Ann. Rheum. Dis. 31, 345-358 (1972).
13. Appel, H., et al. immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum. 54, 2845-2851 (2006).
14. Appel, H., et al. immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum. 54, 1805-1813 (2006).
15. François, R. J., Neure, L., Sieper, J. & Braun, J. immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann. Rheum. Dis. 65, 713-720 (2006).
16. Benjamin, M. & McGonagle, D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J. Anat. 199, 503-526 (2001).
17. Benjamin, M. & McGonagle, D. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv. Exp. Med. Biol. 649, 57-70 (2009).
18. Baeten, D., et al. Diagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients. Arthritis Rheum. 50, 2931-2941 (2004).
19. + macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum. 50, 1611-1623 (2004).
20. Vandooren, B., et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum. 60, 966-975 (2009).
21. Feldmann, M. & Maini, S. R. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol. Rev. 223, 7-19 (2008).
22. Tracey, D., Klareskog, L., Sasso, e. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244-279 (2008).
23. Brown, M. A., et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 40, 1823-1828 (1997).
24. Brown, M. A., Laval, S. H., Brophy, S. & Calin, A. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann. Rheum. Dis. 59, 883-886 (2000).
25. Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis consortium (TASC); Burton, P. R., et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39, 1329-1337 (2007)
26. Australo-Anglo-American Spondyloarthritis consortium (TASC); Reveille, J. D., et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat. Genet. 42, 123-127 (2010).
27. Cui, X., Rouhani, F. N., Hawari, F. & Levine, S. J. An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding. J. Biol. Chem. 278, 28677-28685 (2003).
28. Thomas, G. P. & Brown, M. A. Genetics and genomics of ankylosing spondylitis. Immunol. Rev. 233, 162-180 (2010).
29. Layh-Schmitt, G. & Colbert, R. A. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr. Opin. Rheumatol. 20, 392-397 (2008).
30. van den Berg, W. B. & Miossec, P. iL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 549-553 (2009).
31. Genovese, M. C., et al. LY2439821, a humanized anti-iL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum. 62, 929-939 (2010).
32. Khan, M. A. epidemiology of HLA-B27 and arthritis. Clin. Rheumatol. 15 (Suppl. 1), 10-12 (1996)
33. Hammer, R. e., Maika, S. D., Richardson, J. A., Tang, J. P. & Taurog, J. D. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 63, 1099-1112 (1990).
34. Milia, A. F., et al. HLA-B27 transgenic rat: an animal model mimicking gut and joint involvement in human spondyloarthritides. Ann. NY Acad. Sci. 1173, 570-574 (2009).
35. Taurog, J. D., et al. inflammatory disease in HLA-B27 transgenic rats. Immunol. Rev. 169, 209-223 (1999)
36. Brown, M. A. Genetics and the pathogenesis of ankylosing spondylitis. Curr. Opin. Rheumatol. 21, 318-323 (2009).
37. Khan, M. A. in HLA System in Biology and Medicine: A Resource Book (ed. Mehra, N.) 422-446 (Jaypee Brothers Medical Publishers, New Delhi, 2010).
38. Reveille, J. D. Recent studies on the genetic basis of ankylosing spondylitis. Curr. Rheumatol. Rep. 11, 340-348 (2009).
39. Reveille, J. D. & Maganti, R. M. Subtypes of HLA-B27: history and implications in the pathogenesis of ankylosing spondylitis. Adv. Exp. Med. Biol. 649, 159-176 (2009).
40. Gorga, J. C., Madden, D. R., Prendergast, J. K., Wiley, D. C. & Strominger, J. L. Crystallization and preliminary X-ray diffraction studies of the human major histocompatibility antigen HLA-B27. Proteins 12, 87-90 (1992).
41. Madden, D. R., Gorga, J. C., Strominger, J. L. & Wiley, D. C. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 70, 1035-1048 (1992).
42. Van Kaer, L. Major histocompatibility complex class i-restricted antigen processing and presentation. Tissue Antigens 60, 1-9 (2002).
43. Zhao, L., Fong, Y., Granfors, K., Gu, J. & Yu, D. identification of cytokines that might enhance the promoter activity of HLA-B27. J. Rheumatol. 35, 862-868 (2008).
44. Chapman, D. C. & Williams, D. B. eR quality control in the biogenesis of MHC class i molecules. Semin. Cell. Dev. Biol. doi:10.1016/j.semcdb.2009.12. 013.
45. Kanaseki, T., Blanchard, N., Hammer, G. e., Gonzalez, F. & Shastri, N. eRAAP synergizes with MHC class i molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. Immunity 25, 795-806 (2006).
46. Yan, J., et al. In vivo role of eR-associated peptidase activity in tailoring peptides for presentation by MHC class ia and class ib molecules. J. Exp. Med. 203, 647-659 (2006).
47. Turner, M. J., Delay, M. L., Bai, S., Klenk, e. & Colbert, R. A. HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum. 56, 215-223 (2007).
48. Colbert, R. A., DeLay, M. L., Layh-Schmitt, G. & Sowders, D. P. HLA-B27 misfolding and spondyloarthropathies. Prion 3, 15-26 (2009).
49. Smith, J. A., et al. endoplasmic reticulum stress and the unfolded protein response are linked to synergistic iFN-beta induction via X-box binding protein 1. Eur. J. Immunol. 38, 1194-1203 (2008).
50. Dong, W., et al. Upregulation of 78-kDa glucose-regulated protein in macrophages in peripheral joints of active ankylosing spondylitis. Scand. J. Rheumatol. 37, 427-434 (2008).
51. Gu, J., et al. Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles. J. Rheumatol. 29, 2159-2164 (2002).
52. Young, A. C., Zhang, W., Sacchettini, J. C. & Nathenson, S. G. MHC class i\peptide interactions and TCR recognition. Cancer Surv. 22, 17-36 (1995).
53. López de Castro, J. A. HLA-B27 and the pathogenesis of spondyloarthropathies. Immunol. Lett. 108, 27-33 (2007).
54. Atagunduz, P., et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum. 52, 892-901 (2005).
55. Fiorillo, M. T., Maragno, M., Butler, R., Dupuis, M. L. & Sorrentino, R. CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J. Clin. Invest. 106, 47-53 (2000).
56. Zou, J., Appel, H., Rudwaleit, M., Thiel, A. & Sieper, J. Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Ann. Rheum. Dis. 64, 722-729 (2005). (Pubitemid 40559299)
57. Kollnberger, S. & Bowness, P. The role of B27 heavy chain dimer immune receptor interactions in spondyloarthritis. Adv. Exp. Med. Biol. 649, 277-285 (2009).
58. Kollnberger, S., et al. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum. 46, 2972-2982 (2002).
59. Kollnberger, S., et al. HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired ig-like receptors. J. Immunol. 173, 1699-1710 (2004).
60. Kollnberger, S., et al. interaction of HLA-B27 homodimers with KiR3DL1 and KiR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide. Eur. J. Immunol. 37, 1313-1322 (2007).
61. Chan, A. T., Kollnberger, S. D., Wedderburn, L. R. & Bowness, P. expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KiR3DL2 in spondylarthritis. Arthritis Rheum. 52, 3586-3595 (2005).
62. Ben Dror, L., Barnea, E., Beer, I., Mann, M. & Admon, A. The HLA-B*2705 peptidome. Arthritis Rheum. 62, 420-429 (2010).
63. López de Castro, J. A. The HLA-B27 peptidome: building on the cornerstone. Arthritis Rheum. 62, 316-319 (2010).
64. Hülsmeyer, M., et al. Dual, HLA-B27 subtype-dependent conformation of a self-peptide. J. Exp. Med. 199, 271-281 (2004).
65. Rückert, C., et al. Conformational dimorphism of self-peptides and molecular mimicry in a disease-associated HLA-B27 subtype. J. Biol. Chem. 281, 2306-2316 (2006).
66. Baeten, D., Kruithof, E., Breban, M. & Tak, P. P. Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum. 58, 730-733 (2008).
67. Nocturne, G., et al. Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AiR) registry. Ann. Rheum. Dis. 69, 471-472 (2010).
68. Milia, A. F., et al. evidence for the prevention of enthesitis in HLA-B27/hbeta2m transgenic rats treated with a monoclonal antibody against TNFalpha. J. Cell. Mol. Med. doi:10.1111/j.1582-49342009.00984.x.
69. Breban, M., et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J. Immunol. 156, 794-803 (1996).
70. Breban, M., Hammer, R. E., Richardson, J. A. & Taurog, J. D. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J. Exp. Med. 178, 1607-1616 (1993).
71. May, E., et al. CD8 alpha beta T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. J. Immunol. 170, 1099-1105 (2003).
72. Taurog, J. D., et al. Spondylarthritis in HLA-B27/human beta2-microglobulin-transgenic rats is not prevented by lack of CD8. Arthritis Rheum. 60, 1977-1984 (2009).
73. Dhaenens, M., et al. Dendritic cells from spondylarthritis-prone HLA-B27-transgenic rats display altered cytoskeletal dynamics, class ii major histocompatibility complex expression, and viability. Arthritis Rheum. 60, 2622-2632 (2009).
74. Fert, I., et al. Correlation between dendritic cell functional defect and spondylarthritis phenotypes in HLA-B27/HUMAN beta2-microglobulin-transgenic rat lines. Arthritis Rheum. 58, 3425-3429 (2008).
75. Armaka, M., et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J. Exp. Med. 205, 331-337 (2008).
76. Benjamin, M. & McGonagle, D. Basic concepts of enthesis biology and immunology. J. Rheumatol. Suppl. 83, 12-13 (2009).
77. Benjamin, M., et al. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum. 56, 224-233 (2007).
78. Mathieu, A., et al. The interplay between the geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis. Autoimmun. Rev. 8, 420-425 (2009).
79. Rashid, T. & ebringer, A. Ankylosing spondylitis is linked to Klebsiella-the evidence. Clin. Rheumatol. 26, 858-864 (2007).
80. Hannu, T., inman, R., Granfors, K. & Leirisalo-Repo, M. Reactive arthritis or post-infectious arthritis? Best Pract. Res. Clin. Rheumatol. 20, 419-433 (2006).
81. Appel, H., et al. Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis. Arthritis Res. Ther. 6, R521-R534 (2004).
82. inman, R. D. Mechanisms of disease: infection and spondyloarthritis. Nat. Clin. Pract. Rheumatol. 2, 163-169 (2006).
83. Braun, J., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 38, 499-505 (1995).
84. Smolen, J. S., et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis. 68, 823-827 (2009).
85. Lories, R. J., Derese, I., de Bari, C. & Luyten, F. P. evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum. 56, 489-497 (2007).
86. Maksymowych, W. P. Disease modification in ankylosing spondylitis. Nat. Rev. Rheumatol. 6, 75-81 (2010).
87. Neidhart, M., et al. expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in longstanding ankylosing spondylitis. Ann. Rheum. Dis. 68, 1334-1339 (2009).
88. Walsh, N. C. & Gravallese, e. M. Bone remodeling in rheumatic disease: a question of balance. Immunol. Rev. 233, 301-312 (2010).
89. Lories, R. J., Luyten, F. P. & de Vlam, K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res. Ther. 11, 221 (2009).
90. Lories, R. J. & Luyten, F. P. Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev. 16, 287-298 (2005).
91. Winkler, D. G., et al. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J. Biol. Chem. 279, 36293-36298 (2004).
92. van Bezooijen, R. L., et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199, 805-814 (2004).
93. Schett, G., Zwerina, J. & David, J. P. The role of Wnt proteins in arthritis. Nat. Clin. Pract. Rheumatol. 4, 473-480 (2008).
94. Diarra, D., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156-163 (2007).
95. Lories, R. J., Derese, i. & Luyten, F. P. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J. Clin. Invest. 115, 1571-1579 (2005).
96. Appel, H., et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 60, 3257-3262 (2009).
97. Daoussis, D., et al. evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 62, 150-158 (2010).